Related Experiment Video
Updated: Feb 23, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
Noncognitive Behavioral Changes Associated With Alzheimer's Disease: Implications of Neuroimaging Findings
Jeff Victoroff1, Feng V Lin1, Kerry L Coburn1
1From the Department of Psychiatry, University of Southern California, Rancho Palos Verdes, Calif. (JV); the Departments of Nursing, Psychiatry, Neuroscience, and Brain and Cognitive Science, University of Rochester, Rochester, N.Y. (FVL); the Department of Psychiatry, Mercer University School of Medicine, Macon, Ga. (KLC, SDS); the University of Cambridge, Department of Psychiatry, Cambridge, United Kingdom, and Cambridgeshire and Peterborough NHS Foundation Trust (VV); and the Departments of Psychiatry, Neurology and Neurosurgery, Montreal Neurological Institute and McGill University Health Centre, McGill University, Montreal, Quebec, Canada (SD).
Abstract:
Alzheimer's disease (AD) is commonly associated with noncognitive behavioral changes (NCBCs). The authors systematically reviewed whether neuroimaging has helped with understanding the pathophysiology, diagnosis, or management of NCBCs associated with AD, including depression, aggression or agitation, anxiety, apathy, psychosis, and sleep disorder. The authors identified dissociable neural substrates with multimodal imaging: depression implicates the lateral and superior prefrontal cortex; apathy and agitation implicate the dorsal anterior cingulate; psychosis implicates right lateralized frontal and medial temporal areas; and anxiety implicates mesial temporal regions. Frontal white matter changes appear to underlie many NCBCs, emphasizing the preventative management of vascular risk factors. Further delineation of underlying neurocircuitry and pathophysiology in larger data sets might lead to biomarker identification for diagnosis and optimizing treatment targets.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive Development During Adulthood
Dementia
The progression of dementia is generally gradual....

